Navigation Links
Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
Date:2/16/2009

TAMPA, Fla., Feb. 16 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that it has entered into an agreement with Advanced Vision Research, Inc. (AVR) of Woburn, MA, to co-promote, within the U.S., AVR's new MacuTrition(R) oral retinal nutritional supplement and its recently launched NutriDox Convenience Kit for meibomian gland therapy.

AVR is a privately held ophthalmic specialty company and manufacturer of the popular over-the-counter TheraTears(R) dry-eye product line. The Sirion sales force will promote MacuTrition and the NutriDox Convenience Kit and provide sampling for the TheraTears line.

"The partnership with Advanced Vision Research continues and expands our mission to offer diversified products that will make a real difference to ophthalmologists and their patients," said Barry Butler, President and CEO of Sirion. "MacuTrition, the NutriDox Convenience Kit and the TheraTears product line dovetail strongly with our own products in development for dry AMD, dry eye and other ocular conditions."

"Sirion and Advanced Vision Research share a joint focus on healthy eyes for patients through clinical research and innovation in ocular disease," commented Jeffrey P. Gilbard, M.D., AVR founder, CEO and Chief Scientific Officer. Dr. Gilbard is Clinical Assistant Professor of Ophthalmology at Harvard Medical School, and Director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center in Boston. "Sirion's resources and specialized sales force will be instrumental in helping AVR promote retinal and meibomian gland health and provide relief for dry-eye patients."

MacuTrition is the first major oral nutritional supplement that addresses oxidation, inflammation and neovascularization, three very important processes that threaten long-term eye and general health, and play a key role in t
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
5. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
6. Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...o also Visit Detroit , (V...French Ambassador for International Investment, an... , , , ,What: Ambassador Appia is available to me...atives adopted by France to further develop the fi...ion and development., , ,When: Available for Inter...
(Date:11/24/2009)...rio, Nov. 24 Dow AgroSci...ssets of Hyland Seeds, a division of Thompsons Lim...Seeds will further expand Dow AgroSciences, curren...troduction of SmartStax(TM) in 2010 and Dow ...n corn in 2012. The transactional close is expecte...
(Date:11/24/2009)... employment grew by 29,000 jobs in October, and t...rowth during the U.S. recession. However, clinics ...lth systems are coming closer to having to actuall...ators. , (Vocus) November...ing in October despite the shedding of jobs in mos...
(Date:11/24/2009).... 24 NeurogesX, Inc. (Na... on developing and commercializing novel pain mana...onno, President and Chief Executive Officer, is sc...y Health Care Conference, to be held December 1-2,...w York. ,, Mr. DiTonno and Stephen Ghiglieri, ...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
...rocessing Services selected BMC Software ,s MAIN...esponse time of its credit card and credit applica...ervices provides outsourced credit receivables man...Fiserv Credit Processing Services provides clients...nage credit decisions, account acquisition, accoun...
...many ways to share information. But most of us rel...oint. , ,We all use portals of various types. News...hat portals. Some of us use project management, da...all these are now available not only as stand alon...ns that are available 24/7. , ,The problem is tha...
...tion , a global supply chain technology solutions ...a-Pacific headquarters in Shanghai, China. With an...sixty employees by the end of 2004. The office is ...t development for the Far East. RedPrairie is the ...adquarters in China. , ,"Creating a strong presen...
Other Biology Technology:E-Mail Collaboration Problems 2E-Mail Collaboration Problems 3E-Mail Collaboration Problems 4
(Date:11/24/2009)...upus Research Institute (LRI) today named 12 new g...6 million, recognize innovative work across a broa...r their creativity, novelty, and potential to driv...t, and cure the complex disease of systemic lupus....d lupus researchers across the nation and include ...
(Date:11/24/2009)...ger and the American College of Medical Toxicology... the publication of the Journal of Medical Toxico...inning in March 2010. It was previously published... Journal of Medical Toxicology , an international... the science and practice of medical toxicology. ...
(Date:11/24/2009)... release is available in Spanish . , The pr... levels of inflammatory substances in the blood, h... shown by a research project of the University of ...cientist at the School of Pharmacy. , The projec... in relation to the control of body weight and inf...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Springer and the American College of Medical Toxicology to work together 2It can be predicted the reaction obese patients will have to a diet 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3Newly found DNA catalysts cleave DNA with water molecule 9589 1Newly found DNA catalysts cleave DNA with water molecule 9589 2
...in a key brain protein known to underlie a form of...nting the normal growth and branching of neurons, ...alfunction of the protein made by mutant forms of ...ultimately leading to their death. The loss of dop...y of PD, and loss of connections among such neuron...
... simple stream of one-letter characters in the hum...de. In order to decipher this level of architectu...ental and algorithmic methods to detect copy numbe...duplications of DNA segments. These technologies-...were used to create the first comprehensive map of...
...g reasons behind the dramatic increase in testicul...ong 15-to-35-year-old Caucasian men, is the focus ...tute (NCI) grant to Yale Public Health researcher ... for unknown reasons and this study will provide i...netic and other risk factors,?said Zheng, professo...
Other Biology News:Parkinson's mutation stunts neurons 2New technology used to construct the first map of structural variation in the human genome 2
...53; Agarose Gel-Digesting Preparation contains a u... EPICENTRE for simple, quantitative recovery of in...ose gels following electrophoresis in TAE, TBE, MO...directly in the TAE, TBE, MOPS, and phosphate elec...
...heer in-house demand is causing shortages in your ...s antibody. This can cause unwanted distractions, ...for your hard work and endeavour! Bring us your id...nally. We work under ISO 9001 quality assurance in...
...assays for interferons are cytopathic effect inhib...ys. Sample types include; tissue culture supernat...ons. In these assays, one unit is defined as the ...reduce the cytopathic effect of viral infection by...
Mae II from Roche Applied Science
Biology Products: